These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 9225787

  • 21. In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas.
    Reubi JC, Waser B, van Hagen M, Lamberts SW, Krenning EP, Gebbers JO, Laissue JA.
    Int J Cancer; 1992 Apr 01; 50(6):895-900. PubMed ID: 1348240
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.
    Bakker WH, Albert R, Bruns C, Breeman WA, Hofland LJ, Marbach P, Pless J, Pralet D, Stolz B, Koper JW.
    Life Sci; 1991 Apr 01; 49(22):1583-91. PubMed ID: 1658515
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.
    Breeman WA, Hofland LJ, van der Pluijm M, van Koetsveld PM, de Jong M, Setyono-Han B, Bakker WH, Kwekkeboom DJ, Visser TJ, Lamberts SW.
    Eur J Nucl Med; 1994 Apr 01; 21(4):328-35. PubMed ID: 7911760
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
    De Jong M, Bakker WH, Breeman WA, Bernard BF, Hofland LJ, Visser TJ, Srinivasan A, Schmidt M, Béhé M, Mäcke HR, Krenning EP.
    Int J Cancer; 1998 Jan 30; 75(3):406-11. PubMed ID: 9455802
    [Abstract] [Full Text] [Related]

  • 30. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.
    Janson ET, Westlin JE, Ohrvall U, Oberg K, Lukinius A.
    J Nucl Med; 2000 Sep 30; 41(9):1514-8. PubMed ID: 10994731
    [Abstract] [Full Text] [Related]

  • 31. In vivo localization of [(111)In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector.
    Rogers BE, McLean SF, Kirkman RL, Della Manna D, Bright SJ, Olsen CC, Myracle AD, Mayo MS, Curiel DT, Buchsbaum DJ.
    Clin Cancer Res; 1999 Feb 30; 5(2):383-93. PubMed ID: 10037188
    [Abstract] [Full Text] [Related]

  • 32. Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus: Implications for the in vivo visualization during somatostatin receptor scintigraphy.
    Ferone D, Pivonello R, Kwekkeboom DJ, Gatto F, Ameri P, Colao A, de Krijger RR, Minuto F, Lamberts SW, van Hagen PM, Hofland LJ.
    J Endocrinol Invest; 2012 May 30; 35(5):528-34. PubMed ID: 21765239
    [Abstract] [Full Text] [Related]

  • 33. Synthesis and characterisation of [90Y]-Bz-DTPA-oct: a yttrium-90-labelled octreotide analogue for radiotherapy of somatostatin receptor-positive tumours.
    Smith-Jones PM, Stolz B, Albert R, Ruser G, Briner U, Mäcke HR, Bruns C.
    Nucl Med Biol; 1998 Apr 30; 25(3):181-8. PubMed ID: 9620621
    [Abstract] [Full Text] [Related]

  • 34. In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats.
    Bakker WH, Krenning EP, Reubi JC, Breeman WA, Setyono-Han B, de Jong M, Kooij PP, Bruns C, van Hagen PM, Marbach P.
    Life Sci; 1991 Apr 30; 49(22):1593-601. PubMed ID: 1658516
    [Abstract] [Full Text] [Related]

  • 35. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.
    Krenning EP, Bakker WH, Kooij PP, Breeman WA, Oei HY, de Jong M, Reubi JC, Visser TJ, Bruns C, Kwekkeboom DJ.
    J Nucl Med; 1992 May 30; 33(5):652-8. PubMed ID: 1349039
    [Abstract] [Full Text] [Related]

  • 36. Autoradiographic analysis of somatostatin SRIF1 and SRIF2 receptors in the human brain and pituitary.
    Thoss VS, Piwko C, Probst A, Hoyer D.
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Feb 30; 355(2):168-76. PubMed ID: 9050008
    [Abstract] [Full Text] [Related]

  • 37. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies.
    Vezzosi D, Bennet A, Rochaix P, Courbon F, Selves J, Pradere B, Buscail L, Susini C, Caron P.
    Eur J Endocrinol; 2005 May 30; 152(5):757-67. PubMed ID: 15879362
    [Abstract] [Full Text] [Related]

  • 38. New trends in peptide receptor radioligands.
    Virgolini I, Traub T, Novotny C, Leimer M, Füger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M, Andreae F, Kurtaran A, Dudczak R.
    Q J Nucl Med; 2001 Jun 30; 45(2):153-9. PubMed ID: 11476164
    [Abstract] [Full Text] [Related]

  • 39. Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors.
    Hofland LJ, De Herder WW, Visser-Wisselaar HA, Van Uffelen C, Waaijers M, Zuyderwijk J, Uitterlinden P, Kros MJ, Van Koetsveld PM, Lamberts SW.
    J Clin Endocrinol Metab; 1997 Sep 30; 82(9):3011-8. PubMed ID: 9284735
    [Abstract] [Full Text] [Related]

  • 40. Somatostatin receptors on neuroendocrine tumors--a way to intraoperative diagnosis and localization.
    Ahlman H, Tisell LE, Wängberg B, Nilsson O, Fjälling M, Forssell-Aronsson E.
    Yale J Biol Med; 1994 Sep 30; 67(3-4):215-21. PubMed ID: 7502530
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.